BioCam
Capsule endoscopy + AI · Gastrointestinal diagnostics
Overview
Next-generation wireless capsule endoscopy with AI image analysis for affordable gastrointestinal screening.
What they do
BioCam (BioCam S.A.) is a Polish medtech startup developing a next-generation wireless capsule-endoscopy system with AI image analysis for gastrointestinal diagnostics. The swallowable capsule images the digestive tract and uses AI algorithms for pathology recognition, with the goal of making GI screening more affordable and accessible than conventional endoscopy. The company has positioned its technology around features such as selective lighting modules and NBI-style imaging combined with an AI pathology-recognition module.
Lead program & status
The lead product is the BioCam capsule-endoscopy platform. The company has assembled funding from multiple sources: it reported raising a total of around PLN 10.5 million (including roughly PLN 5 million in an NCBR grant and PLN 5.5 million from investors), secured a PLN 2 million investment from Level2 Ventures, and was awarded EU regional funding under the European Funds for Lower Silesia 2021-2027 (project value reported near PLN 8 million) to develop the AI-equipped capsule. As of 2024 the company was closing an investment round and signaling a planned debut on the NewConnect market (reported for Q2-Q3 2024), with the product still in development toward commercialization.
Why it matters
Capsule endoscopy avoids the discomfort and sedation of traditional procedures; pairing it with AI triage could lower cost and expand GI screening - relevant for early detection of colorectal and other digestive-tract disease.
FAQ
- What is BioCam building?
- A next-generation wireless capsule-endoscopy system with AI-based pathology recognition for affordable gastrointestinal diagnostics.
- How is BioCam funded?
- It has reported roughly PLN 10.5 million raised (including an NCBR grant), a PLN 2 million Level2 Ventures investment, and EU regional funding for Lower Silesia.
- Is BioCam publicly listed?
- As of 2024 the company signaled a planned NewConnect debut (reported for Q2-Q3 2024) while still advancing the product toward market.
Technology
BioCam works in AI-Driven Drug Discovery — Compressing years of trial-and-error chemistry into months of computation.
Read the AI-Driven Drug Discovery brief →Related companies
Company website / source ↗ Open the interactive map →
Get ahead of the next biotech boom.
New companies, stage changes, deal alerts and fresh tech briefs — one sharp email when the map moves.